Neurocrine Biosciences: NBI-921352
Kayak Study
TCSF is thrilled to announce that Neurocrine Biosciences' SCN8A study is now enrolling.
This is a study to evaluate NBI-921352 as adjunctive therapy in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) in patients age 2-21. This is the first SCN8A specific clinical trial and is a huge step forward for our community!
SENTINEL COHORT:
The DEE2012 “KAYAK” study will enroll in two parts: a Sentinel Cohort of 8 participants and a Main Cohort of up to 52 participants. There will be a pause in participants screening and enrollment for data analysis by an independent data monitoring committee (DMC) and any needed protocol amendments following the full enrollment of the Sentinel Cohort.
SENTINEL COHORT:
The DEE2012 “KAYAK” study will enroll in two parts: a Sentinel Cohort of 8 participants and a Main Cohort of up to 52 participants. There will be a pause in participants screening and enrollment for data analysis by an independent data monitoring committee (DMC) and any needed protocol amendments following the full enrollment of the Sentinel Cohort.
To learn more about this study, you or your doctor may contact the study research staff:
Neurocrine Medical Information Call Center
877-641-3461
medinfo@neurocrine.com
ClinicalTrials.gov identifier (NCT number): NCT04873869
Neurocrine Medical Information Call Center
877-641-3461
medinfo@neurocrine.com
ClinicalTrials.gov identifier (NCT number): NCT04873869
Trial Sites
(Currently USA only, more sites to come)
|
Recruiting
|
Not Yet Recruiting
|
|
|
The Cute Syndrome is registered as a tax-exempt organization under IRS section 501(c)(3).
Our tax identification number is: 46-2699066. © The Cute Syndrome Foundation, All rights reserved
|
